Sunday, 20 September 2026European Markets

SCHEERD.V KERCHOVE Stock Over 17% Down So Far On Tuesday

Loading stream...

(VIANEWS) - Shares of SCHEERD.V KERCHOVE (BEL 20: SCHD.BR) slid by a staggering 17.29% to €488.00 at 14:21 EST on Tuesday, following the last session's upward trend. BEL 20 is falling 1.26% to €3,702.66, after three successive sessions in a row of gains. This seems, up until now, an all-around down trend trading session today.

SCHEERD.V KERCHOVE's last close was €550.00, 14.06% under its 52-week high of €640.00.

About SCHEERD.V KERCHOVE

Scheerders van Kerchove's Verenigde fabrieken nv manufactures and distributes building materials. It offers façade panels, slates, facing bricks, and corrugated sheets. The company was founded in 1905 and is based in Sint-Niklaas, Belgium.

Earnings Per Share

As for profitability, SCHEERD.V KERCHOVE has a trailing twelve months EPS of €-3.3.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is negative -15.06%.

Revenue Growth

Year-on-year quarterly revenue growth declined by 4.1%, now sitting on 39.97M for the twelve trailing months.

More news about SCHEERD.V KERCHOVE (SCHD.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Boom Hits a Fork: Slowdown Calls Clash with Capex Confidence as Markets Get Nervous
Dario Amodei's repeated calls for a global slowdown in frontier AI development, echoed by Microsoft's new humanist AI code of conduct and FTC antitrust caution, are being publicly rejected by Nvidia and Meta leadership even as hyperscaler spending draws fresh skeptical scrutiny (Wachter's analysis, Burry-style overbuilding worries) and weak guidance from Adobe and a post-slowdown-comment selloff in GE Vernova signal investor jitters. Meanwhile wealth and security effects of the AI race keep compounding — Zhang Yiming's fortune surging on AI-driven ByteDance value, a Chinese hacking firm weaponizing AI against stolen government secrets, and low-quality AI-generated products (an AI sitcom, a spam-flooding agent platform) fueling backlash even as adoption races ahead.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Berkshire Hathaway
Both facts report Berkshire Hathaway's cash position on 2026-01-01 with identical observation timestamps, but claim vastly different values: 380 billion USD vs 400 USD. These cannot both be true for the same entity at the same point in time. The magnitude of the discrepancy (a factor of ~10^9) rules out rounding, unit conversion, or methodological differences.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,982
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,982 facts checked against source5,299 source documents archived
Query this data → isubstrate.com